Ackermans & van Haaren leads EUR 60 million Series B Financing Round for Confo Therapeutics, a Belgian clinical-stage biopharmaceutical company
26 July 2024 - 3:00PM
UK Regulatory
Ackermans & van Haaren leads EUR 60 million Series B Financing
Round for Confo Therapeutics, a Belgian clinical-stage
biopharmaceutical company
Dear shareholder,
Dear Madam, Dear Sir,
please find attached our press release.
Best regards
Ackermans & van Haaren
- Ackermans & van Haaren leads EUR 60 million Series B
Financing Round for Confo Therapeutics (press release 26 July
2024)
Ackermans and Van Haaren... (EU:ACKB)
Historical Stock Chart
From Oct 2024 to Nov 2024
Ackermans and Van Haaren... (EU:ACKB)
Historical Stock Chart
From Nov 2023 to Nov 2024